Thriving After Lung Cancer, Thanks to a Clinical Trial

One cancer patient’s immunotherapy clinical trial, an approach with hopeful results, could have implications for others seeking treatment.

7:00 AM

Author | Beth Uznis Johnson

Every cancer patient who joins a clinical trial runs the risk of not responding to the new drug or treatment being studied. That outcome didn't keep Myles Widmer from feeling hopeful.

MORE FROM MICHIGAN: Sign up for our weekly newsletter

The 73-year-old had two choices: "I could die sitting there doing nothing or I could die fighting," he says. "I decided to fight."

His fight was ongoing. After a diagnosis of stage 3 non-small cell lung cancer in 2011, Widmer was treated with chemotherapy and radiation. For a while, everything looked good.

But in April of 2013, surveillance scans showed that his cancer recurred; he now had stage 4 lung cancer. Widmer went through two different chemotherapy treatments. Both provided only short-term benefit and didn't stop the cancer from growing.

Under the care of Shirish M. Gadgeel, M.D., co-leader of the Thoracic Oncology Research Program at the University of Michigan Comprehensive Cancer Center, Widmer agreed to participate in an immunotherapy clinical trial.

How immunotherapy works

Immunotherapy is a newer approach to treating cancer that harnesses the body's own immune system to attack cancer cells. Normally, the immune system should be able to attack cancer cells. But cancers, as they grow, fool the patient's immune system into thinking that it is normal tissue.

SEE ALSO: Immunotherapy: The Future of Cancer Treatment?

Through a range of techniques, immunotherapy can help a patient's immune system recognize the cancer, attack it and thus:

  • Stop or slow the growth of cancer cells

  • Stop cancer from spreading to new parts of the body

  • Help the immune system better destroy cancer cells

Widmer began the trial treatment in November 2013. And while prior research suggested the patient's condition was unlikely to change, the effects were significant.

"For years, it was thought immunotherapy wouldn't work for lung cancer," Gadgeel says. "For Mr. Widmer, it produced dramatic benefits. His cancer shrank very much. After two years, his treatment stopped.

"Two years after that, there has been no progression of the cancer on his scans."

Wider-reaching benefits

Not only is Widmer alive and well today, his personal decision to participate in clinical research has the potential to benefit others. He was one of the trial's few patients whose cancer responded to treatment, giving researchers vital clues to developing future cures.

"Never before have we had the level of excitement and hope we have now because of advances in research," Gadgeel says. "My expectation is that results from initial immunotherapy drugs will be built upon to develop new combinations that expand the pool of patients that derive such benefits."

SEE ALSO: Depression and Cancer: Why Emotional Care Is Key During Treatment

Widmer visits the Cancer Center every three months for scans to monitor his progress. The Garden City, Michigan, resident is now retired and spends his free time watching his three grandsons play baseball, basketball and tennis.

"I go as often as I can to games. I travel to tournaments. I don't have much to do to treat cancer anymore. My scans look good," he says.

Learn about clinical trials for lung and other cancers at the University of Michigan or call the Cancer AnswerLine at 800-865-1125.


More Articles About: Cancer Care lung cancer Cancer Treatment Lungs and Breathing
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of healthcare news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories colorful illustration with human figure and highlighted lungs
Health Lab
Multimodal AI model may guide personalized treatments for tuberculosis
AI approach helps researchers interpret large biomedical data sets to accurately predict tuberculosis treatment prognosis
Provider takes a pulse oximetry reading from a patient's finger
Health Lab
Inaccurate pulse oximeter readings could limit transplants, heart pumps for Black patients with heart failure
Racially biased readings of oxygen levels in the blood using pulse oximeters may further limit opportunities for Black patients with heart failure to receive potentially lifesaving treatments, such as heart pumps and transplants
An unconscious woman lies on a hospital table while a clinician's glove is seen placing an oxygen mask over her nose and mouth
Health Lab
Hispanic patients with respiratory failure much more likely to be oversedated
Hispanic individuals who are hospitalized with respiratory failure are five times more likely than non-Hispanic patients to receive deep sedation while on a ventilator, according to a new study published in the Annals of the American Thoracic Society.
Portrait of Max Wicha, founding director of Rogel Cancer Center
Health Lab
‘We might for the first time really be thinking of cures of cancer’
Founding Rogel Cancer Center Director reflects on how cancer evolved from ‘the least scientific discipline’ to a shining example of how basic research discoveries can change clinical care.
Don Reynolds, seated at right, and his family gather together. Reynolds can garden with his grandchildren after a successful treatment with Pluvicto. Photos courtesy of the Reynolds family
Health Lab
Pluvicto treatment gives patient another chance
New treatment for metastatic castration resistant prostate cancer helped patient get back to his hobbies
sketched out bacteria in a dish yellow and blue colors of U-M
Health Lab
Bacteria in the mouth linked to pulmonary fibrosis survival
Bacteria in the mouth may play a role in survival from idiopathic pulmonary fibrosis (IPF).